Viread – Tenofovir fumarate Tablets

Viread – Tenofovir fumarate Tablets

Brand Name: Viread
Contents: Tenofovir disoproxil fumarate 300mg
Form: Tablets
Manufactured By: Nycomed GmbH, Germany
Country Of Origin: Germany
Packing: Pack of 30 Tablets
  • For discounted prices contact us at +91 9871336968
  • Viread  300 mg
    Indication
    VIREAD (tenofovir disoproxil fumarate) is a prescription medicine used to treat chronic hepatitis B virus (HBV) in 18+ Person. The long-term effects of taking VIREAD for the treatment of chronic hepatitis B infection are not known.
    Viread Tablets are is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.

    The following point should be considered when initiating therapy with tenofovir for the treatment of HIV-1 infection:

    * Tenofovir should not be used in combination with tenofovir /emtricitabine or emtricitabine /tenofovir/efavirenz (see WARNINGS AND PRECAUTIONS)

    Viread DOSAGE AND ADMINISTRATION

    The dose of Viread  300 mg is once daily taken orally, without regard to food.

    Dose Adjustment for Renal Impairment
    Significantly increased drug exposures occurred when tenofovir disoproxil fumarate was administered to patients with moderate to severe renal impairment. The dosing interval of tenofovir disoproxil fumarate should be adjusted in patients with baseline creatinine clearance <50 mL/min using the recommendations in Table 2 .The safety and effectiveness of these dosing interval adjustment recommendations have not been clinically evaluated; therefore, clinical response to treatment and renal function should be closely monitored in these patients.

    No dose adjustment is necessary for patients with mild renal impairment (creatinine clearance 50–80 mL/min). Routine monitoring of calculated creatinine clearance and serum phosphorus should be performed in patients with mild renal impairment

    1.Calculated using ideal (lean) body weight.

    2.Generally once weekly assuming three hemodialysis sessions a week of approximately 4 hours duration. Tenofovir disoproxil fumarate should be administered following completion of dialysis.

    The pharmacokinetics of tenofovir have not been evaluated in non-hemodialysis patients with creatinine clearance <10 mL/min; therefore, no dosing recommendation is available for these patients.

    CONTRAINDICATIONS
    None.